organization · Reporting owner
ARCH Venture Fund VIII Overage, L.P.
Disclosed activity across 8 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Codiak BioSciences, Inc.CDAK · Entity 114958 | 10% owner | September 13, 2022 | September 15, 2022 |
| Metacrine, Inc.MTCR · Entity 115177 | 10% owner | September 18, 2020 | September 22, 2020 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | 10% owner | October 27, 2025 | October 29, 2025 |
| Q32 Bio Inc.FIXX · Entity 5594 | 10% owner | May 21, 2019 | May 23, 2019 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | 10% owner | February 22, 2019 | February 26, 2019 |
| Twist Bioscience CorpTWST · Entity 3619 | 10% owner | November 02, 2018 | November 06, 2018 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | 10% owner | May 07, 2018 | May 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Codiak BioSciences, Inc.
Report date September 13, 2022 · Filed September 15, 2022
Jointly reported with ARCH Venture Fund VIII, L.P., CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SotckSEC Table I · non-derivative | IndirectSee footnotes | 8,854,098 |
Reported balance
After 2022-09-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-09-13 · Purchase · Acquired 5,000,000 · Balance 8,854,098 F1: Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share. F2: Comprised of 7,503,903 shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") and 1,350,195 shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). F3: Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. F4: Shares held by ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-09-13 | Direct | 5,000,000 |
Reported balance
After 2022-09-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-13 · Purchase · Acquired 5,000,000 · Balance 5,000,000 F1: Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share. F3: Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share.
F2: Comprised of 7,503,903 shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") and 1,350,195 shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage").
F3: Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
F4: Shares held by ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Metacrine, Inc.
Report date September 18, 2020 · Filed September 22, 2020
Jointly reported with ARCH Venture Fund VIII, L.P., CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,960,784 |
Reported balance
After 2020-09-18 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-09-18 · Conversion · Acquired 1,960,784 · Balance 1,960,784 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,433,035 |
Reported balance
After 2020-09-18 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-09-18 · Conversion · Acquired 472,251 · Balance 2,433,035 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,571,769 |
Reported balance
After 2020-09-18 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-09-18 · Conversion · Acquired 138,734 · Balance 2,571,769 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,781,769 |
Reported balance
After 2020-09-18 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-09-18 · Purchase · Acquired 210,000 · Balance 2,781,769 F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 138,734 |
Reported balance
After 2020-09-18 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-09-18 · Conversion · Acquired 138,734 · Balance 138,734 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 158,734 |
Reported balance
After 2020-09-18 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2020-09-18 · Purchase · Acquired 20,000 · Balance 158,734 F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-18 · Conversion · Disposed 1,960,784 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-18 · Conversion · Disposed 472,251 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-09-18 · Conversion · Disposed 138,734 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-09-18 · Conversion · Disposed 138,734 · Balance 0 F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
F2: These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Neumora Therapeutics, Inc.
Report date October 27, 2025 · Filed October 29, 2025
Jointly reported with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund XII, L.P. | 6,046,907 |
Reported balance
After 2025-10-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-10-27 · Purchase · Acquired 1,915,700 · Balance 6,046,907 F1: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VII, L.P. | 1,387,228 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,387,228 F2: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VIII Overage, L.P. | 2,321,566 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,321,566 F3: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X, L.P. | 12,205,379 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 12,205,379 F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X Overage, L.P. | 11,886,758 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,886,758 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F2: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F3: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
Q32 Bio Inc.
Report date May 21, 2019 · Filed May 23, 2019
Jointly reported with ARCH Venture Fund VIII, L.P., ARCH Venture Partners VIII, L.P., ARCH Venture Partners VIII, LLC, BYBEE CLINTON, CRANDELL KEITH, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,768,694 |
Reported balance
After 2019-05-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-05-21 · Other · Disposed 300,001 · Balance 5,768,694 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: Following the transactions reported herein, includes 1,137,663 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,631,031 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). F3: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: Following the transactions reported herein, includes 1,137,663 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,631,031 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").
F3: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Sienna Biopharmaceuticals, Inc.
Report date February 22, 2019 · Filed February 26, 2019
Jointly reported with ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII, L.P., ARCH Venture Partners VIII, L.P., BYBEE CLINTON, CRANDELL KEITH, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,900,575 |
Reported balance
After 2019-02-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-02-22 · Purchase · Acquired 150,000 · Balance 2,900,575 F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). F2: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,032,493 |
Reported balance
After 2019-02-22 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-02-22 · Purchase · Acquired 150,000 · Balance 1,032,493 F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). F2: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,865,800 |
Reported balance
After 2019-02-22 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-02-22 · Purchase · Acquired 1,865,800 · Balance 1,865,800 F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). F3: The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell, Robert Nelsen and Steven Gillis are managing directors of AVP X LLC, and they may be deemed to beneficially own the shares held by ARCH X Overage. Messrs. Crandell, Nelsen and Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage").
F2: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell, Robert Nelsen and Steven Gillis are managing directors of AVP X LLC, and they may be deemed to beneficially own the shares held by ARCH X Overage. Messrs. Crandell, Nelsen and Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Twist Bioscience Corp
Report date November 02, 2018 · Filed November 06, 2018
Jointly reported with ARCH Venture Partners VIII, LLC, ARCH Venture Fund VII, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, BYBEE CLINTON, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,182,645 |
Reported balance
After 2018-11-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-02 · Conversion · Acquired 1,182,645 · Balance 1,182,645 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,900,920 |
Reported balance
After 2018-11-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-02 · Conversion · Acquired 718,275 · Balance 1,900,920 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,167,696 |
Reported balance
After 2018-11-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-02 · Conversion · Acquired 266,776 · Balance 2,167,696 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,392,422 |
Reported balance
After 2018-11-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-11-02 · Conversion · Acquired 224,726 · Balance 2,392,422 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,407,422 |
Reported balance
After 2018-11-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-11-02 · Purchase · Acquired 15,000 · Balance 2,407,422 F4: Reflects shares purchased in the Issuer's initial public offering. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 894,146 |
Reported balance
After 2018-11-02 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2018-11-02 · Conversion · Acquired 894,146 · Balance 894,146 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 954,146 |
Reported balance
After 2018-11-02 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-02 · Purchase · Acquired 60,000 · Balance 954,146 F4: Reflects shares purchased in the Issuer's initial public offering. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-11-02 · Conversion · Disposed 1,182,645 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-11-02 · Conversion · Disposed 718,275 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-11-02 · Conversion · Disposed 266,776 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-11-02 · Conversion · Disposed 224,726 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-11-02 · Conversion · Disposed 894,146 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: Reflects shares purchased in the Issuer's initial public offering.
F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F6: The expiration date is not relevant to the conversion of these securities.
Unity Biotechnology, Inc.
Report date May 07, 2018 · Filed May 07, 2018
Jointly reported with ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, CRANDELL KEITH, BYBEE CLINTON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,070,172 |
Reported balance
After 2018-05-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-07 · Conversion · Acquired 2,030,625 · Balance 2,070,172 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,298,604 |
Reported balance
After 2018-05-07 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-05-07 · Conversion · Acquired 4,228,432 · Balance 6,298,604 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 8,365,764 |
Reported balance
After 2018-05-07 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-05-07 · Conversion · Acquired 2,067,160 · Balance 8,365,764 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,486,745 |
Reported balance
After 2018-05-07 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-05-07 · Conversion · Acquired 1,486,745 · Balance 1,486,745 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,682,417 |
Reported balance
After 2018-05-07 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-05-07 · Conversion · Acquired 195,672 · Balance 1,682,417 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-07 · Conversion · Disposed 2,030,625 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-07 · Conversion · Disposed 4,228,432 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-07 · Conversion · Disposed 2,067,160 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-07 · Conversion · Disposed 1,486,745 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-07 · Conversion · Disposed 195,672 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
F2: The expiration date is not relevant to the conversion of these securities.
F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Quanterix Corp
Report date November 20, 2020 · Filed November 24, 2020
Jointly reported with ARCH VENTURE FUND VI LP, ARCH VENTURE PARTNERS VI LP, ARCH VENTURE PARTNERS VI LLC, ARCH Venture Partners VIII, LLC, BYBEE CLINTON, NELSEN ROBERT
Section 16 reporting ended · disclosed 2020-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,182,995 |
Reported balance
After 2020-11-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-20 · Other · Disposed 229,006 · Balance 2,182,995 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund VI, L.P. ("ARCH VI"). ARCH Venture Partners VI, L.P. ("GPLP"), the sole general partner of ARCH VI, may be deemed to beneficially own the shares held by ARCH VI. ARCH Venture Partners VI, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VI. As managing directors of GPLLC, each of Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH VI. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,391,690 |
Reported balance
After 2020-11-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-11-20 · Other · Disposed 145,994 · Balance 1,391,690 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As managing directors of ARCH VIII LLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of ARCH VIII LLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,905,481 |
Reported balance
After 2020-11-24 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-11-24 · Other · Disposed 277,514 · Balance 1,905,481 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2: These shares are directly held by ARCH Venture Fund VI, L.P. ("ARCH VI"). ARCH Venture Partners VI, L.P. ("GPLP"), the sole general partner of ARCH VI, may be deemed to beneficially own the shares held by ARCH VI. ARCH Venture Partners VI, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VI. As managing directors of GPLLC, each of Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH VI. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,214,770 |
Reported balance
After 2020-11-24 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2020-11-24 · Other · Disposed 176,920 · Balance 1,214,770 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As managing directors of ARCH VIII LLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of ARCH VIII LLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 854 |
Reported balance
After 2020-11-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-11-20 · Other · Acquired 854 · Balance 854 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares owned by Nelsen. |
| Common StockSEC Table I · non-derivative | Direct | 853 |
Reported balance
After 2020-11-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-11-20 · Other · Acquired 853 · Balance 853 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares owned by Bybee. |
| Common StockSEC Table I · non-derivative | Direct | 1,888 |
Reported balance
After 2020-11-24 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2020-11-24 · Other · Acquired 1,034 · Balance 1,888 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5: Shares owned by Nelsen. |
| Common StockSEC Table I · non-derivative | Direct | 1,889 |
Reported balance
After 2020-11-24 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2020-11-24 · Other · Acquired 1,036 · Balance 1,889 F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6: Shares owned by Bybee. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2: These shares are directly held by ARCH Venture Fund VI, L.P. ("ARCH VI"). ARCH Venture Partners VI, L.P. ("GPLP"), the sole general partner of ARCH VI, may be deemed to beneficially own the shares held by ARCH VI. ARCH Venture Partners VI, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VI. As managing directors of GPLLC, each of Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH VI. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F3: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As managing directors of ARCH VIII LLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of ARCH VIII LLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
F4: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
F5: Shares owned by Nelsen.
F6: Shares owned by Bybee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries D Preferred Stock · Derivative | 224,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 11 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 224,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries C Preferred Stock · Derivative | 266,776 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 10 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 266,776 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries B Preferred Stock · Derivative | 718,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 9 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 718,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries A Preferred Stock · Derivative | 1,182,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 8 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,182,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | PurchaseCommon Stock | 60,000 | $14.00 | $840,000.00 |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 7 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 954,146 F4 · shares: Reflects shares purchased in the Issuer's initial public offering. F5 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 894,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 6 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 894,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F5 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | PurchaseCommon Stock | 15,000 | $14.00 | $210,000.00 |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 5 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,407,422 F4 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 224,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 4 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,392,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 266,776 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 3 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,167,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 718,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 2 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,900,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 1,182,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 1 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,182,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries C Preferred Stock · Derivative | 195,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 10 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 195,672 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries B Preferred Stock · Derivative | 1,486,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 9 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,486,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries B Preferred Stock · Derivative | 2,067,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 8 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,067,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries A-2 Preferred Stock · Derivative | 4,228,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 7 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,228,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries A-1 Preferred Stock · Derivative | 2,030,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 6 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,030,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 195,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 5 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,682,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 1,486,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 4 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,486,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 2,067,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 3 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,365,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 4,228,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 2 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,298,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 2,030,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 1 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,070,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:25 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries B Preferred Stock · Derivative | 1,385,457 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009446 · doc4.xml · derivative · entry 3 ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,385,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:25 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries A Preferred Stock · Derivative | 4,683,238 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009446 · doc4.xml · derivative · entry 2 ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 4,683,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:25 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionCommon Stock | 6,068,695 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009446 · doc4.xml · nonDerivative · entry 1 ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,068,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries D Preferred Stock · Derivative | 4,087,193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · derivative · entry 13 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,271,684 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F5 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F6 · derivative.expiration_date: Not applicable. F3 · ownership.direct: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VIII LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund Overage. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries D Preferred Stock · Derivative | 1,226,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · derivative · entry 12 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 381,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F5 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F6 · derivative.expiration_date: Not applicable. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries C Preferred Stock · Derivative | 352,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · derivative · entry 11 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F5 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F6 · derivative.expiration_date: Not applicable. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries B Preferred Stock · Derivative | 1,533,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · derivative · entry 10 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 477,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F5 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F6 · derivative.expiration_date: Not applicable. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries A-2 Preferred Stock · Derivative | 3,360,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · derivative · entry 9 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,045,426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F5 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F6 · derivative.expiration_date: Not applicable. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionSeries A-1 Preferred Stock · Derivative | 1,280,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · derivative · entry 8 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 398,257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F5 · derivative.exercise_date: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election. F6 · derivative.expiration_date: Not applicable. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | PurchaseCommon Stock | 266,000 | $15.00 | $3,990,000.00 |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 7 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,684 F4 · shares: Reflects shares purchased in the Issuer's initial public offering. F3 · ownership.direct: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VIII LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund Overage. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 1,271,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 6 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F3 · ownership.direct: The shares are held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VIII LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund Overage. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 381,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 5 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 109,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 4 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,030,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 477,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 3 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 1,045,426 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 2 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,443,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:25 UTC | Quanterix Corp QTRX · Entity 6649 | ConversionCommon Stock | 398,257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-073156 · a4.xml · nonDerivative · entry 1 ARCH VENTURE FUND VI LP · CIK 0001222135 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH VENTURE PARTNERS VI LP · CIK 0001274410 · 10% owner ARCH VENTURE PARTNERS VI LLC · CIK 0001274412 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security. F2 · ownership.direct: The shares are held of record by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. As a managing director of ARCH VI LLC, the Reporting Person may be deemed to beneficially own the shares held by ARCH Fund VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries B Preferred Stock · Derivative | 319,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · derivative · entry 8 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 319,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). GPLLC, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH Overage. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries B Preferred Stock · Derivative | 211,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · derivative · entry 7 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 211,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own certain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH VIII. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries A-3 Preferred Stock · Derivative | 563,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · derivative · entry 6 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 563,072 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). GPLLC, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH Overage. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionSeries A-3 Preferred Stock · Derivative | 2,538,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · derivative · entry 5 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,538,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own certain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH VIII. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 319,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · nonDerivative · entry 4 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 882,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). GPLLC, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH Overage. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 563,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · nonDerivative · entry 3 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 563,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). GPLLC, as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH Overage. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 211,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · nonDerivative · entry 2 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,750,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own certain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH VIII. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| August 01, 2017 Filed Aug 1, 2017 16:30 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | ConversionCommon Stock | 2,538,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-029602 · doc1.xml · nonDerivative · entry 1 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,538,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own certain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. Keith Crandell and Clinton Bybee are managing directors of GPLLC, and as such may be deemed to beneficially own the shares held by ARCH VIII. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.